<!-- /* Font Definitions */ @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;} @font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-1610611985 1073750139 0 0 159 0;} @font-face {font-family:ArialUnicodeMS-Identity-H; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-alt:"Arial Unicode MS"; mso-font-charset:129; mso-generic-font-family:auto; mso-font-pitch:auto; mso-font-signature:1 151388160 16 0 524288 0;} @font-face {font-family:TimesNewRomanPSMT; panose-1:2 2 6 3 5 4 5 2 3 4; mso-font-alt:"Yu Gothic"; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536859921 -1073711039 9 0 511 0;} @font-face {font-family:MinionPro-Regular; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-alt:"Times New Roman"; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:auto; mso-font-signature:1 0 0 0 9 0;} @font-face {font-family:"\@ArialUnicodeMS-Identity-H"; mso-font-charset:129; mso-generic-font-family:auto; mso-font-pitch:auto; mso-font-signature:1 151388160 16 0 524288 0;} @font-face {font-family:PlantinStd; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-alt:"MS Mincho"; mso-font-charset:128; mso-generic-font-family:roman; mso-font-pitch:auto; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"\@PlantinStd"; mso-font-charset:128; mso-generic-font-family:roman; mso-font-pitch:auto; mso-font-signature:1 134676480 16 0 131072 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";} span.A6 {mso-style-name:A6; mso-style-priority:99; mso-style-unhide:no; mso-style-parent:""; font-family:"Calibri",sans-serif; mso-bidi-font-family:Calibri; color:black; font-weight:bold;} span.correction {mso-style-name:correction; mso-style-unhide:no;} span.A3 {mso-style-name:A3; mso-style-priority:99; mso-style-unhide:no; mso-style-parent:""; mso-ansi-font-size:9.0pt; mso-bidi-font-size:9.0pt; color:black;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:10.0pt; mso-ansi-font-size:10.0pt; mso-bidi-font-size:10.0pt;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 72.0pt 72.0pt 72.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} -->
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman",serif;}
ABSTRACT   BACKGROUND: Acinetobacter baumannii is an important opportunistic nosocomial pathogen.  Class 1 integrons in A. baumannii plays a significant role in antibiotic resistance. Therefore, this study aimed to investigate the prevalence of integrons and antibiotic resistance pattern in A. baumannii isolated from clinical samples of Iranian patients. METHODS: The Medical Subject Headings (MeSH) and the keywords with the help of Boolean operators (“AND” or “OR”) were used alone or in combination to conduct the search.  The searching process was conducted in the Web of Science, PubMed, Cochrane Library, Scopus, and Google Scholar databases and, also Iranian databases.  The search was restricted to relevant English and Persian cross-sectional publications reporting the prevalence of Int1 in A. baumannii isolated from clinical samples from 1 January 2000 to 31 December 2018.  The data were analyzed using Comprehensive Meta-Analysis software. Regarding the heterogeneity of studies, the random effects model was used. Cochrane Q and I2 tests was used to evaluate statistical heterogeneity between the studies. RESULTS: Fifteen studies were included in the analysis. The combined prevalence of class 1 integrons in A. baumannii was 55.2% (95% CI: 44.8-65.1). The pooled prevalence of MDR A. baumannii isolates was 68.1%. The highest resistance belonged to Aztreonam, followed by Ciprofloxacin, and Ceftazidime with a resistance rate of 97.6%, 92.8%, and 91.6%, respectively. Tobramycin was reported as an effective antibiotic. CONCLUSIONS: The present study reported an alarmingly high prevalence of class 1 Integrons, and MDR isolates of A. baumannii recovered from clinical samples that should be considered. KEYWORDS: Prevalence, Integrons, Acinetobacter baumannii, Pathogen